VBL Therapeutics to Initiate P-II Study Evaluating VB-111 (ofranergene obadenovec) + Nivolumab in Patients with Metastatic Colorectal Cancer

 VBL Therapeutics to Initiate P-II Study Evaluating VB-111 (ofranergene obadenovec) + Nivolumab in Patients with Metastatic Colorectal Cancer

VBL Therapeutics to Initiate P-II Study Evaluating VB-111 (ofranergene obadenovec) + Nivolumab in Patients with Metastatic Colorectal Cancer

Shots:

  • The focus of the study is to evaluate the safety & tolerability of the combination therapy in addition to ORR as well as immunological and histologic readouts from tumor biopsies. The clinical study will be the first study to evaluate the combination of VB-111 with a checkpoint inhibitor
  • The National Cancer Institute (NCI) will serve as an IND sponsor which has been approved by the US FDA. The study is expected to highlight the potential of VB-111 to turn “cold” colorectal tumors “hot”
  • VB-111 is the first VTS-based therapy targeting the tumor vasculature for cancer therapies. The addition of nivolumab to the therapy may synergize the anti-tumor effect of VB-111

Click here ­to­ read full press release/ article | Ref: VBL | Image: VBL

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post